Novel lipid-lowering therapies in development will expand options for managing cardiovascular risk and targeting dyslipidemia biomarkers, especially in high-risk and statin-intolerant patients.
Answers are grounded in this paper and cite their sources.
May inform pipeline monitoring for high-risk dyslipidemia; leaves open outcome trials to confirm net benefit.
Optimizing the use of available first- and second-line lipid-lowering drugs allows us to adequately control low-density lipoprotein cholesterol (LDL-C) levels, even in statin-intolerant individuals and in patients at high and very high risk of developing cardiovascular diseases who must reach more aggressive LDL-C targets. The drugs under development will further improve our ability to manage the overall lipid-related cardiovascular disease risk and target other dyslipidemia biomarkers.
No takes yet. Share an insight, caveat, or question.
ALGhasab et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: